Senotherapeutika in der Krebstherapie - Zelluläre Seneszenz als therapeutisches Ziel

What if senescent tumor cells trigger relapse after chemotherapy—and could be specifically eliminated? Senotherapeutics in Cancer Therapy – Cellular Senescence as a Therapeutic Target Prof. Dr. Bernd Kaina | University Medical Center Mainz, Institute of Toxicology iQMedix Therapist Congress 2026 – Modern Personalized Tumor Medicine, Mannheim In this presentation, Prof. Dr. Bernd Kaina, Emeritus Director of the Institute of Toxicology at the University Medical Center Mainz, provides a scientific overview of cellular senescence (CSEN) as a mechanism in tumor therapy and the growing importance of senotherapeutics in oncology. Topics of this presentation: – Fundamentals of cellular senescence: from the Hayflick limit to therapy-induced senescence (TIS) – DNA damage response (DDR): the ATM/ATR-CHK-p53 axis and its role in cell cycle arrest, apoptosis, and senescence – The SASP (senescence-associated secretory phenotype) as a pro-inflammatory factor in tumors and healthy tissue – Evidence for TIS in various tumor entities – clinical and translational data – Senolytics, senomorphic agents, and senopreventive agents: mechanisms of action, substance classes, and natural compounds (fisetin, quercetin, artesunate, curcumin, dasatinib) – Clinical trials – Organ senescence and biomarkers: proteomics-based approaches to assessing biological age About the speaker: Prof. Dr. Bernd Kaina is one of Germany's leading scientists in the field of DNA repair and tumor toxicology. For decades, he has researched temozolomide resistance, DNA damage-induced signaling pathways, and senescent tumor cells. His research group has made fundamental contributions to the study of senolysis in glioblastoma cells. 🔬 This presentation is intended for physicians, scientists, and medical professionals. Further information on iQMedix molecular tumor diagnostics: 🔗 https://www.iqmedix.eu?utm_source=you... ⚠️ Mandatory Notice / Disclaimer: This presentation was given at the iQMedix Therapists' Congress 2026 and is intended exclusively for medical professionals (physicians, pharmacists, naturopaths, and medical scientists). The information presented here is for scientific education and informational purposes only. It does not constitute a promise of healing, a treatment recommendation, or an invitation to self-medicate. Treatment decisions are solely at the discretion of the treating physician, taking into account the individual patient's situation. The substances mentioned (e.g., fisetin, quercetin, dasatinib, artesunate) are predominantly still in preclinical or early clinical trials as senotherapeutic agents. Advertising of therapeutic effects as defined by the German Medicines Advertising Act (HWG) is not intended. iQMedix GmbH offers molecular diagnostic services and assumes no responsibility for treatment decisions made by third parties.